非创伤性心脏骤停心肺复苏期间及之后的液体治疗:临床前与临床研究的系统评价
该系统评价检索PubMed和Embase从建库至2024年6月的文献,纳入描述液体复苏策略并报告至少一项感兴趣结局(自主循环恢复、存活至入院或出院、急性肾损伤发生率、神经功能结局)的成人非创伤性心脏骤停临床前与临床研究,排除评估复苏期间碳酸氢盐缓冲治疗和/或使用冷液体输注诱导低温的研究。共纳入29项研究,包括10项临床研究和19项动物模型。心肺复苏期间液体治疗的效果在临床研究中探索不足;高渗盐水治疗在动物模型中作为复苏期间替代复苏液体出现;复苏后设置中平衡晶体液被越来越多地评估;尚无临床研究探讨早期目标导向液体复苏对结局(特别是休克缓解和神经功能恢复)的影响。作者结论呼吁临床证据评估心肺复苏期间液体复苏的有效性和安全性,明确高渗盐水在复苏期间及之后的位置,并将早期目标导向液体治疗作为复苏后集束化治疗的个体化干预实施。
要点
- 共纳入29项研究,包括10项临床研究和19项动物模型,心肺复苏期间液体治疗的效果在临床研究中探索不足。
- 高渗盐水治疗在动物模型中作为心肺复苏期间的替代复苏液体出现。
- 复苏后设置中平衡晶体液被越来越多地评估。
- 尚无临床研究探讨早期目标导向液体复苏对结局(特别是休克缓解和神经功能恢复)的影响。
- 作者呼吁临床证据评估心肺复苏期间液体复苏的有效性和安全性,并明确高渗盐水在复苏期间及之后的位置。
适用人群与场景
- 成人非创伤性心脏骤停患者(临床研究)及动物模型(临床前研究),涵盖心肺复苏期间和复苏后阶段。
研究设计与关键结果
- 系统评价检索PubMed和Embase从建库至2024年6月,纳入描述液体复苏策略并报告至少一项感兴趣结局的成人非创伤性心脏骤停临床前与临床研究,排除评估复苏期间碳酸氢盐缓冲治疗和/或使用冷液体输注诱导低温的研究。
- 共纳入29项研究,包括10项临床研究和19项动物模型。
- 心肺复苏期间液体治疗的效果在临床研究中探索不足。
- 高渗盐水治疗在动物模型中作为心肺复苏期间的替代复苏液体出现。
- 复苏后设置中平衡晶体液被越来越多地评估。
- 尚无临床研究探讨早期目标导向液体复苏对结局(特别是休克缓解和神经功能恢复)的影响。
证据类型、等级与局限
- 证据类型:系统评价,纳入10项临床研究和19项动物模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需要临床证据评估心肺复苏期间液体复苏的有效性和安全性,明确高渗盐水在复苏期间及之后的位置,并将早期目标导向液体治疗作为复苏后集束化治疗的个体化干预实施。
指南或共识出处
- 系统评价注册:PROSPERO;注册号:CRD42024571617;网址:https://www.crd.york.ac.uk/prospero/。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Several therapeutic interventions are recommended during and after cardiopulmonary resuscitation (CPR) in order to optimize oxygen delivery and improve survival rates. Among these interventions, there is a clinical practice heterogeneity regarding use of fluids in this setting. The optimal fluid resuscitation strategy remains controversial. This systematic review aimed to summarize the current knowledge regarding type, dosing, and safety of fluid therapy during and after CPR in animal models and human studies. Methods: A systematic search of the literature within PubMed and Embase was conducted from database inception to June 2024. Preclinical and clinical studies involving adult patients with nontraumatic cardiac arrest describing fluid resuscitation strategies and reporting at least one outcome of interest were included: achievement of return of spontaneous circulation, survival to hospital admission or discharge, incidence of acute kidney injury and neurological outcome. Studies assessing intra-arrest bicarbonate buffer therapy and/or using cold fluid infusions to induce hypothermia were excluded. Results: Twenty-nine studies met inclusion criteria, including 10 clinical studies and 19 animal models. The effects of fluid therapy during CPR are underexplored in clinical research. Hypertonic saline therapy has emerged as an alternative resuscitative fluid during CPR in animal models. In postresuscitation setting, balanced crystalloids have been increasingly assessed. There are no clinical studies investigating the impact of early goal directed fluid resuscitation on outcomes in particular shock resolution and neurological recovery. Conclusions: There is a call for clinical evidence to assess the efficacy and safety of fluid resuscitation during CPR, to define the place of hypertonic saline therapy during and after resuscitation and finally to implement early goal-directed fluid therapy as a tailored intervention of the postarrest care bundle. Review registration: ROSPERO; No.: CRD42024571617; URL: https://www.crd.york.ac.uk/prospero/.
参考来源
- Jendoubi A, De Roux Q, Lê MP, et al. FLUID THERAPY DURING AND AFTER CARDIOPULMONARY RESUSCITATION FOR NONTRAUMATIC CARDIAC ARREST: A SYSTEMATIC REVIEW OF EVIDENCE FROM PRECLINICAL AND CLINICAL STUDIES. Shock. 2025. PMID: 40016801. doi:10.1097/SHK.0000000000002519
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。